Business
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,527,768, entitled "Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases."
About this update from Neurosense Therapeutics Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Patent protection extended through 2043","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"Alzheimer's proof-of-concept study completed","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical and Biomarker Outcomes Expected in Q1 2026","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":138,"olType":false},{"type":"text","content":"CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the United States Patent and Trademark Office has granted U.S. Patent No. 12,527,768, entitled "Compositions Comprising an Anti-Inflammatory Drug and a Dicer Activator for use in the Treatment of Neuronal Diseases."","length":490,"tagName":"p"},{"type":"image","alt":"NeuroSense Therapeutics Logo","displaySize":"","headline":null,"caption":"NeuroSense Therapeutics Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":160,"url":"https://media.zenfs.com/en/prnewswire.com/488fd1dd822c4adae2c61a5f94250e7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MN2mGlFDOSbLhtTMpnwDsg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI4MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/488fd1dd822c4adae2c61a5f94250e7d","width":400,"height":160}}},{"type":"text","content":"The granted patent provides protection for the use of PrimeC combination in Alzheimer's disease, strengthening NeuroSense's intellectual property estate and supporting the program's long-term development and potential commercialization, with protection extending through 2043.","length":288,"tagName":"p"},{"type":"text","content":""This patent meaningfully expands and reinforces our intellectual property position around the PrimeC combination," said Alon Ben-Noon, Co-Founder and Chief Executive Officer of NeuroSense. "It reflects both the breadth of the underlying biology and our strategy to build durable protection as we advance PrimeC combination clinically in Alzheimer's disease and other neurodegenerative conditions."","length":422,"tagName":"p"},{"type":"text","content":"NeuroSense recently concluded its proof-of-concept ...